Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -29.10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 225.35 | 43.30 | 59.10 | 573.99 | 446.92 | 76.48 | 24.81 | 108.80 | 240.78 | 21.26 | 69.14 | 7.78 | 42.94 | 20.30 | 45.53 | 22.38 | 31.08 | 22.13 | 56.79 | 53.40 | 36.62 |
| — | -43.4% | +138.2% | +427.6% | +85.6% | +259.8% | -64.1% | +1298.7% | +460.7% | +4.7% | +51.8% | -65.2% | +38.2% | -8.3% | -19.8% | -58.1% | -15.1% | -25.0% | +144.9% | -0.9% | +50.4% | |
| P/B Ratio | 5.74 | 7.46 | 5.28 | 4.16 | 5.22 | 3.61 | 2.79 | 3.85 | 4.04 | 3.18 | 4.00 | 3.77 | 2.05 | 3.08 | 3.73 | 2.95 | 2.31 | 2.56 | 5.10 | 7.10 | 6.17 |
| — | +106.4% | +89.1% | +7.9% | +29.4% | +13.5% | -30.3% | +2.1% | +96.5% | +3.4% | +7.2% | +28.0% | -11.3% | +20.2% | -26.8% | -58.5% | -62.5% | -69.8% | -19.1% | -26.9% | +28.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 2763.6% | -2580.7% | 81.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | +22.2% | 0.0% | +2663.6% | -2680.7% | -18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -891.3% | -116.3% | -244.9% | -3422.9% | -3347.4% | -736.8% | -336.8% | -1092.2% | -1927.9% | -198.5% | -562.2% | -40.3% | -1216.3% | -262.7% | -478.8% | -239.4% | -469.9% | -354.4% | -383.8% | -222.5% | -140.8% |
| — | +84.2% | +27.3% | -213.4% | -73.6% | -271.1% | +40.1% | -2608.1% | -58.5% | +24.4% | -17.4% | +83.2% | -158.8% | +25.9% | -24.7% | -7.6% | -233.7% | -165.4% | -445.1% | -122.6% | -153.2% | |
| Net Margin | -794.4% | -94.2% | -201.5% | -3043.0% | -2973.0% | -667.6% | -296.7% | -956.9% | -1670.3% | -164.0% | -472.0% | -30.0% | -1118.2% | -235.0% | -432.4% | -216.0% | -450.2% | -349.6% | -381.3% | -221.9% | -140.5% |
| — | +85.9% | +32.1% | -218.0% | -78.0% | -307.1% | +37.1% | -3089.1% | -49.4% | +30.2% | -9.2% | +86.1% | -148.4% | +32.8% | -13.4% | +2.7% | -220.3% | -162.6% | -445.3% | -123.7% | -155.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.8% | -4.0% | -4.4% | -6.9% | -8.6% | -8.7% | -8.1% | -8.2% | -7.9% | -6.0% | -8.8% | -3.6% | -12.7% | -8.6% | -8.6% | -7.0% | -9.4% | -9.7% | -8.3% | -7.2% | -7.7% |
| — | +53.9% | +45.1% | +15.8% | -8.2% | -44.7% | +7.9% | -125.2% | +37.8% | +30.3% | -2.1% | +47.7% | -34.8% | +11.2% | -4.1% | +3.3% | -22.4% | -5.3% | -76.6% | -64.0% | -92.5% | |
| ROA | -22.9% | -3.7% | -4.1% | -6.1% | -7.4% | -7.5% | -6.9% | -7.0% | -6.7% | -5.0% | -6.7% | -2.5% | -9.3% | -6.5% | -6.7% | -5.6% | -7.4% | -7.4% | -6.3% | -5.4% | -5.3% |
| — | +50.6% | +41.3% | +13.0% | -9.6% | -50.6% | -2.8% | -176.0% | +28.0% | +23.5% | +0.0% | +54.6% | -25.9% | +12.4% | -7.2% | -3.4% | -39.4% | -35.1% | -128.4% | -112.9% | -128.8% | |
| ROIC | -24.9% | -3.9% | -4.5% | -6.6% | -8.5% | -8.4% | -7.0% | -7.2% | -6.9% | -5.4% | -8.1% | -3.8% | -10.1% | -6.9% | -7.4% | -7.1% | -9.5% | -8.2% | -6.6% | -6.6% | -8.0% |
| — | +54.3% | +35.5% | +8.7% | -23.4% | -55.7% | +12.8% | -91.1% | +32.1% | +21.9% | -9.2% | +46.9% | -6.9% | +15.0% | -12.4% | -8.2% | -18.0% | +5.2% | -70.0% | -81.6% | -111.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.05 | 0.05 | 0.09 | 0.09 | 0.11 | 0.11 | 0.10 | 0.13 | 0.12 | 0.21 | 0.20 | 0.17 | 0.15 | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 |
| — | -38.3% | -52.4% | -50.4% | -10.2% | -31.5% | -10.3% | -51.0% | -51.7% | -25.3% | -17.8% | +506.2% | +526.2% | +296.7% | +265.2% | -9.5% | -14.5% | -38.7% | -35.8% | -38.3% | -36.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.47 | 9.83 | 10.81 | 10.47 | 7.38 | 8.32 | 8.49 | 7.53 | 8.55 | 8.45 | 9.57 | 4.73 | 5.95 | 7.06 | 6.65 | 5.88 | 5.42 | 4.60 | 4.88 | 4.88 | 5.75 |
| — | +18.2% | +27.3% | +39.0% | -13.7% | -1.6% | -11.3% | +59.2% | +43.7% | +19.8% | +44.0% | -19.5% | +9.7% | +53.3% | +36.1% | +20.6% | -5.8% | +37.1% | +57.8% | +78.4% | +107.6% | |
| Quick Ratio | 10.47 | 9.91 | 10.81 | 10.47 | 7.38 | 8.32 | 8.49 | 7.53 | 8.55 | 8.45 | 9.57 | 4.73 | 5.95 | 7.06 | 6.65 | 5.88 | 5.42 | 4.60 | 4.88 | 4.88 | 5.75 |
| — | +19.1% | +27.3% | +39.0% | -13.7% | -1.6% | -11.3% | +59.2% | +43.7% | +19.8% | +44.0% | -19.5% | +9.7% | +53.3% | +36.1% | +20.6% | -5.8% | +37.1% | +57.8% | +78.4% | +107.6% | |
| Interest Coverage | -1250.50 | -754.69 | -1133.98 | -1263.54 | — | -708.39 | -909.85 | -1198.19 | -1040.45 | -688.54 | -702.72 | -275.31 | -1288.44 | -807.31 | -743.15 | -600.12 | -1193.50 | -980.88 | -893.73 | -676.98 | -407.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KYMR stock.
Kymera Therapeutics, Inc.'s current P/E is -29.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Kymera Therapeutics, Inc.'s current operating margin is -891.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Kymera Therapeutics, Inc.'s business trajectory between earnings reports.